11/06/2024, 01:37 PM UTC
诺和诺德：一位GLP-1领导者面临日益增长的竞争Novo Nordisk: A GLP-1 Leader Faces Increasing Competition
1. 尽管诺和诺德在糖尿病和减肥市场处于领先地位，但由于竞争加剧和监管风险，其股票仍被评级为卖出。2. Hims & Hers预计将销售NVO的利拉鲁肽的仿制药，可能从明年开始威胁其销售。3. 来自Viking Therapeutics和Amgen的激烈竞争可能导致一种新的同类最佳GLP-1药物，进一步威胁诺和的市场地位。1. Novo Nordisk remains a sell due to increased competition and regulatory risks despite its leadership in the diabetes and weight-loss markets. 2. Hims & Hers anticipates selling a generic version of NVO's liraglutide, threatening sales as soon as next year. 3. Intense competition from Viking Therapeutics and Amgen may result in a new best-in-class GLP-1 drug, further threatening Novo's market position.
---
本文由大语言模型（LLM）生成，旨在为读者提供半导体新闻内容的知识扩展（Beta）。
